Ofatumumab

She gave me these three choices.

One was Overtumumab, also known as Kesimpta, the pen that you have to inject every month.

And the other two were infusions that I would have every six months.

And she only said to me that they're all really effective and very strong and I should choose what I think fits best to me, what I feel most comfortable with, which fits my lifestyle.

I tried to read people's reviews just to see how everybody felt on it, just to get a bit of a sense of What was the general feeling about each medication? And in the end, to me, it was potato, potato, really.

I didn't really know.

So I went with Ophetumumab with Kesimpta, which also had the least side effects, you know, because I thought to myself, I don't even know how it goes.

So let's start with this one first.

Novartis already markets one of those B-cell depleting therapies.

Kesimpta, for relapsing MS, depletes B-cells, and patients inject it themselves once a month.

If remabrutinib is approved in MS, Novartis would hold both a depleting monthly self-injection and a non-depleting pill in the same disease.

How those two would sit side by side is the commercial question these trials open.